Compare CVS Health Corp (CVS) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Nasdaq100 ETF — how do they compare? CVS Health Corp trades at $85.46 (market cap $112.29B), while Nasdaq100 ETF trades at $754.16 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 4.5× CVS Health Corp's market cap, and CVS Health Corp pays a 3.03% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Nasdaq100 ETF for 162 Days on average.
| CVS | QQQ | |
|---|---|---|
Market Cap | $112.29B | $506.92B |
Volume | 7,763,676 | 48,326,518 |
Sector | Health | — |
52-Week High | $110.60 | $759.66 |
52-Week Low | $70.08 | $558.34 |
Typical Hold Time | 83 Days | 162 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
QQQ trades at $757.73, down 0.25% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights comparisons with lower-fee alternatives like QQQM and VOO, while broader market concerns about AI valuations and interest rate impacts create headwinds.
The outlook for QQQ remains tied to technology sector performance and AI-driven growth, though elevated valuations and concentration risk warrant caution. Near-term support lies at $754, with resistance at $760. Investors face balancing growth potential against fee differentials and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
